Scientific Online Resource System

Scripta Scientifica Medica

Dynamics of pathomorphological changes in rat ischemic spinal cord after treatment with recombinant erythropoietin: Experimental study

Alexey Volodchenko, Ravil Giniatullin, Arnold Kosel, Lyudmila Astakhova


Introduction. There is ample current research on new methods of treatment for spinal cord infarction. In this respect, in recent years recombinant erythropoietin (REP) has been gaining increasing interest among medical professionals; REP is a drug with proven protective activity in response to ischemia of different organs and tissues including the brain and the spinal cord.

We aim to study the dynamics of morphological changes in spinal cord ischemic lesion in rats influenced by REP.

Materials and methods. The study was conducted on 40 mature rats. The animals were divided into two series of experiment 20 animals each. The first series of animals was the group of comparison with spinal cord ischemia model. In the second series the animals were administered intraperitoneally 1000 international units (0.0084 mg) of REP in 3, 24, and 48 hours. After the animals had been sacrificed, the spinal cord was removed for further histologic and morphometric study. The obtained results were processed using analysis of variance. The statistical significance of differences between compared parameters of the groups was assessed with the Mann-Whitney U test.

Results. The study of the spinal cord specimen showed that REP administration results in significantly higher levels of normal neurons and blood vessels, and in significantly lower count of chromatolytic neurons and ghost cells at all stages of experiment.

Conclusion. At the early stages of experiment, REP effect increases ischemic tolerance of neurons and enhances the proliferation rate of gliocytes and endotheliocytes with development of a new blood stream.


Spinal Cord; Experimental Ischemia; Pathomorphological and Functional Disorders; Recombinant Erythropoietin

Full Text


Fisher M, Takano K. Baillière's clinical neurology: Cerebrovascular disease. Hachinski V, editor. London: Baillière Tindall; 1995. p. 279-96.

Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia the ischemic penumbra. Stroke. 1981;12:723-5.

Symon L, Branston NM, Strong AJ. The concepts of thresholds of ischaemia in relation to brain structure and function. J Clin Pathol Suppl (R Coll Pathol). 1977;11:149-54.

Siren AL, Fratelli M, Brines M, Goemans C, Casagrande S, Lewczuk P, et al. Erythropoietin prevent neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA. 2001;98;4044-49.

Inagaki S, Kitos S. Peptides in the peripheral nervous system. Progr Brain Res. 1986;66;269-316.

Celik M, Gökmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA. 2002;99;2258-63.

Santhanam AV, Katusic ZS. Erythropoietin and cerebral vascular protection: role of nitric oxide. Acta Pharmacol Sin. 2006;27;1389-94.

Wang L, Zhang Z, Wang Y, Zhang R, Chopp M. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004;35;1732-37.

Masuda S, Nagao M, Takahata K, Konishi Y, Gallyas F Jr, Tabira T, et al. Functional erythropoietin receptor of the cells with keural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem. 1993;268;11208-16.

Sufianova GZ, Usov LA, Sufianov AA, Shapkin AG, Raevskaya LY, Golubev SS. New minimal invasive model of rat spinal cord ischemia. Bull Exp Biol Med. 2002;133;1;116-20.

About The Authors

Alexey Volodchenko
Chelyabinsk Regional Clinical Hospital 3
Russian Federation

Neurosurgeon, Department of Neurosurgery

Ravil Giniatullin
Chelyabinsk State Institute of Laser Surgery

Arnold Kosel
Chelyabinsk State Institute of Laser Surgery

Lyudmila Astakhova
Chelyabinsk State Institute of Laser Surgery

Font Size